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1. Introduction
Colorectal cancer represents the third most prevalent cancer in the United States, and the third
most common cause of cancer-related mortality [1]. Due to the widespread introduction of
screening of asymptomatic patients age 50 and above, the incidence of colorectal cancer has
been declining [2]. Unfortunately the incidence of colorectal cancer in those under the age of
50 is increasing [3]. In its earliest stages colorectal cancer is highly treatable and curable. Cures
in patients with advanced disease are uncommon, but with improved systemic therapies and
oncologic surgery, is increasing over time. However, despite modern therapeutic advances,
less than 20% of patients with distant metastatic disease will be alive and disease free for five
years following the diagnosis [4].
Management of colorectal cancer highlights the importance of oncologic multidisciplinary
care. Surgical adjuvant chemotherapy and chemoradiation therapy have led to improved
outcomes for patients with colon cancer and rectal cancer, respectively. This is one of the factors
associated with a decrease in colorectal cancer mortality over the last decade. Adherence to
treatment guidelines has been shown to be associated with improved patient outcomes
[5].Further refinements in adjuvant therapy will involve molecular risk adaption and im‐
proved selection of patients for chemotherapy and adjuvant chemoradiation therapy, incor‐
poration of molecularly targeted agents into the treatment paradigm, and studies to define
more clearly the optimal time and duration of adjuvant therapy following colorectal surgery.
2. Staging of colon cancer
The pathologic stage of colon cancer is currently based on the seventh version of the American
Joint Commission of Cancer Staging [6]; a simplified version is reproduced in Table 1.
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Pathologic stage is currently the most accurate predictor of those at greatest risk of relapse,
and those most likely to benefit from additional adjuvant therapy. As greater than 80% of
patients with stage I disease are cured with surgery alone additional adjuvant therapy has not
been shown to improve the already favorable prognosis. Patients with stage II and III are at
high risk of systemic relapse and in stage III patients the benefit of adjuvant chemotherapy has
clearly been demonstrated and the data supporting it will be reviewed in section 3. Systemic
therapy for patients with resected stage II disease remains highly controversial and will be
addressed in section 4.
Stage Description 5-year survival
I T1,2, N0 85-95%
II T3,4 N0 60-80%
III Any T, N 1,2, M0 30-60%
IV M1 < 20%
Table 1. Simplified AJCC Staging Classification and Estimated 5-year Survival
3. Treatment of stage III colon cancer
5-Flurouracil -based Adjuvant Chemotherapy
The prodrug 5-flurouracil was synthesized and patented in 1957 [7] and had shown modest
efficacy in the treatment of patients with metastatic colorectal cancer, increasing the median
survival from 6-9 months without therapy to an average of 12-14 months. Initial studies
evaluating its efficacy, combined with the immune modulatory agent levamisole, were
conducted by the North Central Cancer Treatment Group (NCCTG) in the 1980s. In a large,
randomized, prospective trial, involving multiple sites across the United States, patients
treated with 5-flurouracil and levamisole for 12 months were noted to have a 40% reduction
in the relative risk of recurrence, and a 33% reduction in the relative risk of mortality [8]. Long
term follow up data from this study confirms the increased cure rate in association with the
use of adjuvant chemotherapy, not merely the representation of a lead-time bias [9]. Thus 5-
flurouracil became, and remains, the backbone of surgical adjuvant therapy for resected stage
III colon cancer. Levamisole was associated with significant toxicity however, and subsequent
clinical trials demonstrated that 5-flurouracil, modulated by leucovorin, was also associated
with a survival benefit [10] but with less neurological toxicity.
Adjuvant 5-flurouracil -based chemotherapy for colon cancer has been refined over time.
Weekly 5-flurouracil has been administered (Roswell Park regimen) and in a randomized
clinical trial, was demonstrated to be superior to the combination of 5-FU, semustine, and
vincristine [10]. Studies comparing 5-flurouracil combined with leucovorin versus levamisole
demonstrated that 6 months treatment of 5-flurouracil + leucovorin was equivalent to 12
months 5-flurouracil levamisole; 6 months of 5-flurouracil plus levamisole was determined to
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be less effective, in terms of 5-year disease free survival. Thus, six months of therapy is
determined to be the optimal. As will be reviewed the optimal duration of chemotherapy is
currently under active investigation.
It had been noted that in the metastatic setting, meta-analysis of randomized phase II trials
suggested that infusional 5-flurouracil is more active when compared to bolus intravenous 5-
flurouracil [11]. 5-flurouracil has a different mechanism of action when given continuously,
with a greater inhibition of messenger ribonucleic acid (RNA), when compared to bolus 5-
flurouracil, where the action is more directed at targeting DNA synthesis through inhibition
of thymidylate synthetase. Reduced folate (leucovorin) increases the binding of 5-flurouracil
to thymidylate synthase, thereby increasing the efficacy of 5-flurouracil in inhibiting DNA
synthesis (see Figure 1). Although no large, randomized studies comparing bolus 5-flurouracil
compared to infusional 5-flurouracil have been performed, the superior toxicity profile of
infusional 5-flurouracil (less diarrhea, mucositis, and myelosuppression), and the potential for
additive benefit of infusional 5-flurouracil (given its different mechanism of action) have led
to infusional 5-flurouracil combined with bolus 5-flurouracil being used more commonly in
5-flurouracil adjuvant chemotherapy combined with other novel agents.
Oral Fluropyrimidines
Capecitabine is an oral pro-drug which is converted to thymidine phosphorylase into 5-
flurouracil. It has been demonstrated that tumor cells have higher levels of thymidine
phosphorylase and therefore at least theoretically there could be preferential accumulation of
5-FU in tumor cells. In a large phase III study (the X-ACT) trial was found to be non-inferior
to bolus 5-flurouracil/leucovorin (Mayo Clinic regimen) [12]. Therefore capecitabine is
currently approved for patients who are deemed to be suitable candidates for monotherapy,
and is an alternative to bolus or infusional 5- flurouracil. Other oral fluropyrimidines have
been examined for efficacy; UFT is a combination of uracil (a dihydropyrimidine dehydryo‐
genase inhibitor (DPD), the enzyme responsible for metabolizing 5-FU, and tegafur (a 5-FU
prodrug). When evaluated in a randomized phase III study of stage II and III patients, and
compared to bolus flurouracil modulated with leucovorin (Roswell Park regimen) it was found
to be equal in efficacy [13]. UFT was approved for use in much Europe and Asia but has not
been approved for use in the United States.
CapeOx is currently recommended as one of the chemotherapy regimens in the latest version
of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in
Oncology (version 1.2011) for the adjuvant treatment of stage III colon cancer. The NO16968
(XELOXA) trial, a large randomized phase III study of CapeOx versus bolus 5-flurouracil
(Roswell Park) was performed in more than 1,800 stage III colon cancer patients. It showed a
significantly superior three-year disease free survival with CapeOx when compared to the
control arm (71% versus 67%, P = 0.0045) [14]. CapeOx was associated with less febrile
neutropenia and stomatitis than 5FU/LV, although as expected peripheral neuropathy were
more frequent; peripheral neuropathy was observed in a similar proportion of patients
receiving FOLFOX or CapeOx.
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As a consequence of the efficacy of oxaliplatin, demonstrated in the metastatic setting, a large
randomized trial compared the efficacy of infusional 5-FU plus oxaliplatin, and infusional 5-
FU combined with bolus 5-FU (the Multi-center International Study of Oxaliplatin, 5-FU, and
Leucovorin, in the Adjuvant Treatment of Colon Cancer, or MOSAIC Study). Initial data
reported a 23% risk reduction of disease recurrence at three years [15]. Updated 6-year disease-
free survival data demonstrated a 6% improvement in disease-free survival, confirming the
initial positive results [16]. Since 2003 FOLFOX has been the standard-of-care for patients with
resected stage III disease with no contraindications to adjuvant chemotherapy.
Due to the young age of participants in the MOSIAC trial the efficacy of FOLFOX chemother‐
apy has been questioned in elderly patients, given its increased toxicity, primarily peripheral
neuropathy. Pooled analysis of four randomized trials, involving 3,742 patients (of whom 614
were greater or equal to 70 years old) demonstrated that the benefit of FOLFOX chemotherapy
did not differ by age, nor did dose intensity [17]. Thus in patients over the age of 70 who are
deemed appropriate candidates may still benefit from the addition of oxaliplatin, although
very few patients over 80 were included in these studies, thus the data for octogenarians and
nonagenarians is limited.
Oxaliplatin was also evaluated in combination with bolus 5-FU (FLOX); in the National
Surgical Adjuvant Breast Project (NSABP) randomized 2,407 patients with stage II or III colon
cancer to either the Roswell Park regiment (bolus 5-FU modulated with leucovorin) or the
Roswell Park regimen combined with fortnightly oxaliplatin. There was a superior 5-year
disease-free survival with FLOX but not a difference in 5-year overall survival [18].
Adjuvant Irinotecan
Other combination cytotoxic regimens have been subjected to randomized phase III clinical
trial evaluation in the stage III setting. Given the trend to evaluate agents with efficacy in the
metastatic setting, and assume at least the potential for benefit in the adjuvant setting,
irinotecan has been studied in combination with 5-FU. Prior metastatic studies confirmed the
superiority of combination bolus 5-FU plus irinotecan when compared to bolus 5-Flurouracil
monotherapy alone [19], as well as when combined with infusional 5-FU (FOLFIRI) (Douillard
JY, et al. 2000). Thus irinotecan was evaluated in the surgical adjuvant setting for high risk
patients, both combined with bolus 5-FU (IFL) [21] or as FOLFIRI compared to infusional and
bolus 5-flurouracil (LV5-FU2), the PETACC-3 study [22]; neither of these studies demonstrated
a benefit to the addition of irinotecan. Therefore at this time irinotecan is not indicated in the
adjuvant treatment of colon cancer.
Efficacy of Anti-Epidermal Growth Factor Monoclonal Antibodies in the Adjuvant Therapy of Colon
Cancer
Given the efficacy of the anti-epidermal growth factor antibodies cetuximab [23] and panitu‐
mumab [24] in the metastatic setting, it seemed reasonable to explore the efficacy of these
antibodies in the adjuvant setting. A large prospective randomized study evaluated the
efficacy of FOLFOX with or without cetuximab chemotherapy. During the course of the trial
studies demonstrated that the benefit to cetuximab therapy was limited to those patients with
KRAS wild type tumors [25]; thus protocol entry to limited to those patients whose tumors
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harbored a KRAS mutation (see Figure 2). Despite this selection of therapy there was no
improvement in the disease-free survival in the cetuximab treated arm [26].
Figure 1. Possible Explanation for Lack of Efficacy of Anti-Epidermal Growth Factor Antibodies in KRAS Mutant Color‐
ectal Cancer
Efficacy of Anti-Epidermal Growth Factor Monoclonal Antibodies in the Adjuvant Therapy of Colon
Cancer
Colorectal cancer is the first tumor for which anti-angiogenesis therapies have proven to be
effective. The addition of irinotecan plus 5-FU plus the fully humanized anti-vascular endo‐
thelial antibody bevacizumab was associated with a 5 month prolongation in overall survival
when compared to chemotherapy alone in patients with metastatic disease. This suggested a
potential role for this novel targeted agent in the adjuvant therapy of stage III colon cancer.
However two studies, the C08 [27] and the AVANT trial [28], both failed to demonstrate a
disease free survival benefit to the addition of bevacizumab to standard chemotherapy.
Future Cytotoxic Approaches to Adjuvant Colon Therapy
Although irinotecan did not add to the efficacy of adjuvant chemotherapy there is a suggestion
that certain patients with molecular subtypes of colon cancer may benefit from it, possibly
patients with microsatellite instable disease [29] Recent randomized phase III clinical trials
suggests superior efficacy of the three agents (5-FU, oxaliplatin, and irinotecan, or FOLFOXIRI)
when compared to two agents FOLFIRI [30-33]. The efficacy of FOLFOXIRI is under consid‐
eration for testing in a prospective randomized clinical trial compared to FOLFOX chemo‐
therapy.
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Duration of Adjuvant Therapy in Colon Cancer
As discussed previously, the standard duration of adjuvant chemotherapy was initially 12
months when adjuvant therapy was first approved for colon cancer in 1990. As noted previ‐
ously subsequent studies determined that 6 months adjuvant duration was determined to be
equally effective. A prospective randomized trial comparing 3 months of LV5-FU2 when
compared to 6 months 5-flurouracil modulated with leucovorin (Mayo regimen) did not
demonstrate a statistically significant difference in overall survival (P>0.05Given as the trial
was not powered as a non-inferiority study, there are four ongoing studies comparing 3 versus
6 months adjuvant chemotherapy (see table 2). Although there are some differences in the
study design, close to 18,000 patients will be entered on these four studies during this decade.
In order to pool the data from these studies, the International Drug Evaluation of Adjuvant
Chemotherapy (IDEA) was formed to coordinate the data analysis of the pooled results. It is
hoped that by the end of the decade the question of whether or not the shorter course (3 months)
is equally effective will be satisfactorily answered.
Clinical Trial StageEvaluated Start Date Target Accrual Treatment Plan
SCOT* III 3/27/2008 9,500 CapeOx/FOLFOX 6 months vs. CapeOx/FOLFOX 3 months
TOSCA II, III 6/20/2007 3,450
FOLFOX 6 vs. 3 months (plus optional
bevacizumab randomization for stage
IIIc)
GERCOR III 5/2/2009 2,500 FOLFOX 6 vs. 3 months
CALGB/SWOG
C80702 III 7/1/2010 2,500 FOLFOX 6 vs. 3 ± celecoxib/placebo
*Short Course Oncology Therapy
Table 2. Planned Randomized Phase III Studies Evaluating the Duration of Adjuvant Chemotherapy
4. Adjuvant radiation therapy for colon cancer
No prospective data to date has suggested a survival benefit with the addition of radiation
therapy as adjuvant following surgery. Retrospective data suggests that patients with high
risk features for recurrence may receive benefit from radiation, including those who had T4
disease (involving another organ), a positive margin (microscopic residual disease, not true
adjuvant), and clinical perforation had a better disease-free survival with the addition of
adjuvant chemoradiation [34]. One large prospective randomized study evaluating the efficacy
of radiation in colon cancers (non-transverse colon) was inconclusive due to the failure to meet
accrual. The study was underpowered but was not able to demonstrate a benefit of the addition
of radiation to chemotherapy [35]. Treatment decisions have to be made based upon the
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patient’s specific risk factors for local recurrence. At this time the use of radiation as adjuvant
for resected stage III colon cancer is mainly limited to those patients with microscopic residual
disease (positive pathologic margin).
5. Adjuvant treatment of stage II colon cancer
Due to the significantly better prognosis, with the majority of patients being cured with surgery
alone, it is more difficult to demonstrate a significant survival benefit with the use of adjuvant
chemotherapy. The initial adjuvant NCCTG adjuvant study of 5-flurouracil and levamisole
was unable to demonstrate a survival benefit for the chemotherapy arm; this may in part be
due to the higher number of non-cancer-related deaths in the 5-flurouracil treated group [8].
A large randomized, prospective trial of 3,239 patients with resected stage II disease demon‐
strated a 3.6% 5-year improvement in survival following 6 months adjuvant 5-fluorouracil and
leucovorin (Mayo regimen) when compared to observation alone [35]. All agree that if a benefit
exists it is relatively small and that the routine use of chemotherapy is not indicated. Of note,
in the MOSIAC trial, there was no difference in outcome between stage II patients treated with
FOLFOX when compared to infusional and bolus 5-flurouracil chemotherapy. Different
pathologic characteristics may indicate those patients at slightly higher risk of relapse [see
table 3]. Tumor microsatellite instability analysis has been associated with a more favorable
prognosis, as well as a lack of benefit from adjuvant 5-flurouracil chemotherapy in resected
stage II and stage III tumors; in stage II tumors those patients with mismatch repair tumors
had an inferior outcome with the use of 5-fluoruracil adjuvant chemotherapy when compared
to observation [39]. Tumor molecular genotyping is being utilized in order to predict those
stage II tumors most likely to relapse. To date, these genomic tests have not been sufficiently
predictive of those most likely to relapse and are of limited clinical utility [40-41].
Pathologic Feature Reference
Less than 12 Lymph Nodes Analyzed 36, 37
Poorly differentiated 38
Clinical Perforation 38
Table 3. Pathologic Features Associated with a Relatively Adverse Prognosis in Stage II Disease
6. Adjuvant and neoadjuvant approaches in rectal cancer
Rectal adenocarcinomas present a unique challenge given its anatomic location in the pelvis
and the fact that part of the rectum is intraperitoneal and part is extraperitoneal. The vast
majority of rectal malignancies are adenocarcinomas; less common pathologies are gastroin‐
testinal stromal tumor (GIST), carcinoid, squamous, adenosquamous tumors and melanoma.
For the purposes of this chapter we will limit our discussed to rectal adenocarcinomas.
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Compared the large bowel the close proximity of rectum to other local organs such as uro‐
genital system requires different surgical techniques and significantly increases the likelihood
of local relapse after surgery when compared to colon cancer [42]. For this reason, in addition
to total mesorectal excision combination therapeutic options have arisen to decrease local
recurrence. Subsequently, these multimodality therapy approaches have become standard-of-
care in locally advanced rectal cancer. In this book chapter, we aimed to summarize scientific
progression in the field of treatment of locally advanced rectal cancer.
Development of Adjuvant Therapy
The standard care of rectal cancer remains surgery with a total mesorectal excision. However
locally advanced disease were relapsing significantly higher than early stage disease after
surgery-only approach [43]. Rectal cancer transmurally invades the rectal wall directly and
can spread through the lymphatic system to regional lymph nodes. These characteristics of
locally advanced disease put the patients at higher risk of local and distant recurrence which
is associated worse overall survival. Given the high rate of the recurrent disease, combination
treatment approaches have evolved in locally advance rectal cancer over the last two decades.
First, adjuvant radiotherapy and then combined modality therapy (chemotherapy concur‐
rently with radiation therapy) was integrated in standard care to enhance survival outcomes
of locally advanced rectal cancer.
An early prospectively randomized clinical trial was conducted to assess the question of
the  adjuvant  benefit  roles  of  radiation,  chemotherapy,  or  combined  modality  therapy
(chemoradiation) in the treatment of locally advance rectal cancer by the Gastrointestinal
Tumor  Study  Group  (GTSG)  in  1985  [44].  In  this  study,  patients  after  having  curative
surgery (202 in  total),  were  enrolled and randomized into four  different  groups includ‐
ing; patients received no adjuvant treatment, patients treated with adjuvant radiotherapy
either at dose of 40 or 48 Gray, patients received adjuvant chemotherapy with semustine
and  5-fluorouracil,  and  a  final  group  treated  with  combination  of  chemotherapy  and
radiotherapy.  All  patients  were  followed  up  to  for  80  months.  Although  there  was  no
significant  difference  for  OS  in  four  groups,  authors  found  significantly  better  disease-
free survival in combination therapy arm compared to resection-alone [44]. In same study,
recurrence  rate  was  highest  in  resection-alone  with  55%,  while  the  lowest  relapse  was
observed in  combination therapy group (33%).  The follow-up results  of  this  study con‐
firmed a significantly improved overall survival reported in combination treatment group
compared to surgery alone group [45]. By the end of the 10 year follow up, 10-year survival
rates were 26% vs. 45% in control group vs. combination treatment group and was showing
the  superiority  of  combination  treatment  group.  Independently,  The  National  Surgical
Adjuvant and Breast and Bowel Project (NSABP) released the result of R-01 that compar‐
ing adjuvant radiation or chemotherapy to surgery alone and provided superior overall
and disease-free survival in chemo group respect to the surgery alone (P = 0.03, P = 0.006
respectively) [46]. No significant survival benefit observed in radiation alone group.
The North Central Cancer Treatment Group (NCCTG) reported a trial comparing the adjuvant
radiation versus the combined chemoradiation. In this study, total 209 patients randomized
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in two arms. The combined modality arm was found to have 34% reduced overall recurrence
compared to the radiation alone. (P < 0.003) [47]. Decreased recurrence incidence was observed
in both local (25% versus 13% P < 0.02) and distant relapse (43% versus 29.5% P < 0.003). After
this study National Surgical Adjuvant Breast Program (NSABP) examined the impact of the
adjuvant chemotherapy alone versus chemoradiotherapy on overall survival and disease free
survival in protocol R-02. In this study, all female patients received 5-flurouracil and leuco‐
vorin whereas male patients either received MOF regimen including 5-flurouracil, semustine,
vincristine or 5-flurouracil combined with leucovorin. Radiotherapy was given in 25 fractions
at a daily 18 Gray dose. Although there was a significant decrease in cumulative local relapse
incidence after 5-year follow-up (13% versus 8%, P = 0.02), they observed no overall or disease-
free survival differences in between these two groups.
Neoadjuvant Radiotherapy
Absence of clinical evidence to use radiotherapy in adjuvant settings urged the researchers to
test the efficacy of radiotherapy in preoperative settings. Swedish investigators conducted a
phase III clinical trial to understand the possible role of neoadjuvant radiotherapy (i.e. pre-
operative radiation therapy) [48]. They enrolled 1,168 patients and randomly assigned to
receive either conventional surgery alone or surgery with preceded neoadjuvant radiotherapy
designed as a total dose of 25 Gy in five fractions. After five years follow up, recurrence rate
was found 11% in neoadjuvant radiotherapy group, whereas it was observed as high as 27%
in patients with surgery alone (P < 0.001). Additionally, the authors reported significantly
better five year-survival in radiotherapy arm (58% compared to 48%, P = 0.004). Since con‐
ventional surgery was performed in this study, the additive role of the radiation in TME was
still not clear. In 2007, this question was addressed by Dutch Colorectal Cancer Group. They
conducted a randomized clinical trial enrolled the patients into TME alone and 5 fractions
radiotherapy with total 25 Gray dose plus total mesorectal excision [49]. After a median 6.1
years follow- up, no significant overall survival difference was demonstrated. Moreover, there
was no significant difference in distal recurrence incidence. On the other hand, they found a
significant decrease in local recurrence rate (5.6 % vs 10.9%, P < 0.001).
Currently, two different preoperative radiotherapy protocols are commonly preferred in
locally advanced rectal cancer treatment including conventional (50.4 Gray administered in 28
fractions) and short-term treatment (25 Gray in 5 fractions). Although both models have been
shown to decrease local recurrence, there are debates on prolonged side effect in short-term
radiotherapy modality [50]. While short-term neoadjuvant radiation treatment is commonly
used in European countries, conventional radiation is standard-of-care of locally advance
rectal cancer in USA.
Neoadjuvant Chemoradiation Therapy (Combined Modality Therapy)
Better outcomes observed in chemoradiation in adjuvant settings raised the question of
possible neoadjuvant chemoradiation for treatment of patients with locally advanced rectal
cancer. In 2004, German Rectal Cancer Study Group (GRCSG) examined the role preoperative
chemoradiation in rectal cancer patients with T3 or T4 stages or node positivity [51]. They
randomized 823 patients in two groups; the neoadjuvant arm received a total 50.4 Gray dose
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radiation in 28 fractions and 5-flurouracil 120-hour continuous infusion during the first and
fifth weeks of radiation at a dose of 1,000 mg per square meter of body surface then followed
by surgery after completing the chemoradiation. Patients also received four cycles of 5-
flurouracil (500 mg per square meter body surface) which was designed as five time weekly
during the four weeks. The adjuvant group also received the same treatment except additional
a boost of 5.4 Gray radiation after total mesorectal excision. No significant difference was
reported for five year-survival in between neoadjuvant and adjuvant group (74% vs 76%
respectively, P = 0.80). Interestingly, five years cumulative incidence of local recurrence was
significantly lower in neoadjuvant group than the adjuvant. (6% versus 13% respectively, P =
0.006). Moreover they observed less acute and long term toxicity in neoadjuvant arm of the
study compared the adjuvant arm (P = 0.001 versus P = 0.01).
In another study, European Organization for Research and Treatment of Cancer (EORTC)
randomized 1,011 patients with locally advanced rectal cancer into four different groups: a)
preoperative radiotherapy designed as 45 Gy in five weeks, b) preoperative radiotherapy plus
two course of 5-flurouracil and leucovorin (350 mg/m2/day and 20 mg/m2/day), c) preoperative
radiotherapy plus postoperative four course of 5-flurouracil and leucovorin, and d) preoper‐
ative radiotherapy and two course of bolus 5-flurouracil and leucovorin, plus postoperative
four course of postoperative 5-flurouracil and leucovorin. In early preliminary results of the
study, authors reported a significant benefit towards preoperative chemoradiotherapy groups
for tumor size, lymph node involvement, pathological complete response (P < 0.0001, P = 0.046,
P < 0.001). [52]. Later in follow up results, no significant difference was observed in OS between
neoadjuvant chemoradiotherapy and neoadjuvant radiotherapy (P=0.085). On the other hand,
local recurrence was significantly lower in preoperative chemoradiation groups (P = 0.002)
[53]. Chemotherapy protocol which was given in this study was an uncommon protocol
possibly is a contributing factor for absence of survival difference in between chemoradiation
and radiation alone group in preoperative settings.
To better understand the additive role of neoadjuvant chemoradiation for patients with locally
advanced rectal cancer, NSABP R-03 trial was conducted. Two hundreds and sixty-seven
patients enrolled in two arms; patients who received neoadjuvant or adjuvant chemoradiation.
Neoadjuvant group received a bolus of 5-flurouracil with leucovorin for six weeks followed
by radiation given as a total 45 Gray dose in 25 fractions with an additional 5.4 Gray boost.
Then, patients were resected and postoperatively received 24 more weeks of weekly 5-FU and
LV. Patients in adjuvant arm also received same courses of treatment in the same order except
initial surgical resection. The most striking finding of this study was superior 5-year disease-
free survival observed in neoadjuvant arm (64.7% vs 53.4%, P=0.011). Although there was not
a significant difference in OS (P = 0.65), There was trend for observed five-year overall survival
as 74.7% vs 65.6% in the neoadjuvant and adjuvant arms respectively [54]. Overall, all these
clinical trials support the use neoadjuvuvant chemotheradiation as standart-care-of locally
advance colorectal cancer. Although there is no clear result proving as an evidence for the
superior OS compared to adjuvant chemoradiation, decreased local recurrence incidence with
neoadjuvant treatment promises better local disease control. Moreover decreased acute and
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prolonged treatment related toxicities and improved sphincter preservation observed in
preoperative treatment also favor the neoadjuvant chemoradiation modality [54].
Current Drugs for Neoadjuvant Therapy of Rectal Cancer
5-Fluorouracil
5-flurouracil has become the recommended first-line chemotherapy in locally advanced rectal
cancer patients based on the GTSG and NCCTG data [44,47].The most commonly preferred
administration mode of 5-flurouracil is continuous intravenous infusion( 225-300mg/m2 daily).
To compare the bolus administration with continuous intravenous infusion, the NCCTG
randomized 660 patients in two arms. Both arms received concurrent radiotherapy. First group
received bolus 5-flurouracil on three consecutive days as s rapid infusion of 500 mg/m2 while
the other group received as protracted infusion (225 mg/m2/day). Four-year relapse free
survival was 63% in continuous infusion group while it was 53% in the bolus arm (P = 0.01).
Significant difference for 4-year overall survival was also observed in the same study. Four-
year overall survival was 70% as compared to 60% in continuous infusion and bolus group
respectively (P = 0.005). Interestingly, no benefit was observed for local relapse in continuous
infusion group (P = 0.110). While leukopenia was more common in bolus group, diarrhea
incidence was found higher in continuous infusion group.
Capecitabine
Since superior outcomes observed in continuous intravenous administration of 5-flurouracil
in chemoradiation regimens, an equivalent fluropyrimidine, capecitabine was studied for
locally advanced rectal cancer treatment. Oral administration of capecitabine which has very
similar pharmacokinetics to continuous intravenous 5-flurouracil provided more convenient
treatment for patients if they are able to tolerate oral administration. In a phase I clinical study,
the recommended dose of the capecitabine was determined as 1800 mg/m2 daily given orally
in two divided doses combined with 50.4 Gray preoperative radiation [56]. A prospectively
randomized study of 1,987 patients was enrolled into two groups; a) patients who received
capecitabine orally, b) patients who were administered bolus 5-flurouracil modulated with
leucovorin [58]. In the results of this study, non-inferior disease-free survival was observed in
capecitabine group. The capecitabine improved relapse-free survival (P = 0.04). Moreover,
fewer adverse effects were seen with capecitabine treatment compared to bolus 5-flurouracil
plus leucovorin arm (P < 0.001) [58].
The NSABP R-04 trial compared the use of capecitabine to continuous infusion 5-flurouracil
with or without oxaliplatin during combined modality therapy in locally advance rectal cancer.
5-fluorouracil was given as a 225 mg/m2 daily protracted venous infusion during radiation and
capecitabine was given at 1650 mg/m2 orally in two divided doses daily on the days of radiation
only. There was no significant different regarding pathologic complete response, surgical
downstaging or sphincter-saving surgery. Local recurrence and overall survival have yet to
be reported [59].
More recently, in a randomized phase III study, German researchers compared the efficacy of
capecitabine with 5-flurouracil as neoadjuvant radiosensitizing agent [60]. In this study, 392
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patients were randomized into two groups. Patients in capecitabine arm were enrolled to
receive two cycles of capecitabine (2,500 mg/m2 days 1-14, repeated day 22), then followed by
chemoradiotherapy (50 4 Gray plus capecitabine 1650 mg/m2 days 1-38 and additionally three
cycles of capecitabine). Two cycles of bolus 5-flurouracil (500 mg/m2 days 1-5, repeated day
29), followed by chemoradiotherapy (50 4 Gray plus infusional 5-flurouracil 225 mg/m2 daily),
finally two cycles of bolus 5-FU were administered patients in 5-flurouracil arm. Results were
promising for non-inferiority with significantly better 5-year OS in capecitabine group (76%
as compared to 67%, P = 0.05). Similarly disease-free survival was also higher in capecitabine
group (75% versus 67%, P = 0.07).
Oxaliplatin
Given the promising results of oxaliplatin treatment of colon cancer in adjuvant setting [15]
and metastatic disease [61] its possible additive effect to the neoadjuvant treatment of rectal
cancer has been investigated. In a phase II clinical trial, oxaliplatin (at 50 mg/m2 on days 1, 8,
22, and 29) plus capecitabine (1,650 mg/m2 on days 1 to 14 and 22 to 35) with radiotherapy (50.4
Gray in 28 fraction) was tested both for activity and safety [62]. Pathologic complete response
was achieved in 17% patients whereas 53/103 patients showed more than 50% tumor regres‐
sion. Although results were not superior to standard 5-FU treatment phase III trials were
warranted. The randomized phase III Studio Terapia Adiuvante Retto ( STAR)-01 trial has
tested to outcomes of addition of oxaliplatin (60 mg/m2) to chemoradiation (225 mg/m2/day
plus 50.4 Gray in 28 daily fractions) comparing with standard chemoradiation [62]. Addition
of oxaliplation did not increase pathologic complete response rate (16% versus 16% ) but rather
increased grade 3 to 4 adverse events in oxaliplatin arms (P < 0.001).
Recently published German CAO/ARO/AIO-04 randomised phase III trial also investigated
the role of oxaliplatin in neoadjuvant chemoradiation [63]. In the study control group was
treated with standard 5-flurouracil-based combined modality treatment, consisting of
preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil (1000 mg/m2 days 1-5 and
29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 days 1-5 and 29).
Oxaliplatin arm received preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil
(250 mg/m2 days 1-14 and 22-35) and oxaliplatin (50 mg/m2 days 1, 8, 22, and 29), followed by
surgery and eight cycles of adjuvant chemotherapy with oxaliplatin (100 mg/m2 days 1 and
15), leucovorin (400 mg/m2 days 1 and 15), and again infusional 5-flurouracil. Authors reported
better pathologic complete response outcomes in oxaliplatin treatment arm compared to
standard group (17% vs 13% respectively, P = 0.038). Controversially, ACCORD 12/0405-
PRODIGE 2 trial reported no benefit with additional oxaliplatin [64]. In this study control
patients were assigned to receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions
with concurrent capecitabine 800 mg/m2 twice daily (5 days per week). The experimental arm
of the study received 50 Gray in 25 fractions radiation with capecitabine 800 mg/m2 twice daily
(5 days per week) and oxaliplatin 50 mg/m2 (once weekly). Although there was trend toward
oxaliplatin plus group for pCR it was not significant (19.2% s 13.9% P=0.09). Preoperative grade
3 and 4 toxicities were observed significantly higher in oxalipatin plus arm (P < 0.001). Since
there is no consensus in clinical trials for benefit with additional oxaliplatin it is not currently
standard-of-care of locally advanced rectal cancer.
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Targeted Therapies
Monoclonal antibodies targeting the critical survival signaling pathways such as epidermal
growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are
currently under the investigation to determine their role in neoadjuvant chemoradiaton
treatment in rectal cancers. The potential role of cetuximab and bevacizumab in the treatment
of locally advanced rectal cancer has been tested in phase I and phase II clinical trials.
In a phase I/II clinical study the safety and potential benefit of cetuximab in neoadjuvant
chemoradiation investigated in locally advanced rectal cancer patients. Forty patients enrolled
to receive initial intravenous dose of 400 mg/m2 cetuximab which was given 1 week before the
initiation of radiation followed by 250 mg/m2/week for 5 weeks and capecitabine during the
radiotherapy 650 mg/m2 orally twice daily and 825 mg/m2 twice daily, as a second dose level
[65]. Observed pathologic complete response was only in two patients (5%), while diarrhea
was seen in 65% of the patients. Grade 3 diarrhea was detected in 15% of cases. In one patient
three grade 4 toxic effect was reported by authors; one myocardial infarction, one pulmonary
embolism, and one pulmonary infection with sepsis.
In the EXPERT-C trial, combination of cetuximab and capecitabine plus oxaliplatin was studied
in neoadjuvant settings. One hundred sixty-five patients enrolled in two arms to receive four
cycles of capecitabine/oxaliplatin and then capecitabine chemoradiotherapy, surgery, and
adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab [66]. In this study
the most striking finding was significantly improved OS in cetuximab plus group (P = 0.034).
Additionally, a better radiologic response was determined in cetuximab group. On the other
hand there was no difference either in pathologic complete response rate or progression-free
survival (P = 1.0, P = 0.363 respectively)
Another fully humanized monoclonal antibody, that binds circulating anti-vascular epithelial
growth factor, bevacizumab, has also been investigated in combination neoadjuvant treatment
of rectal cancer. In a phase I/II study, bevacizumab combined with preoperative 5-FU and
radiotherapy in 32 locally advanced rectal cancer patients [67]. Patients were administered
four cycles of bevacizumab infusion (5 or 10 mg/kg) on day 1 of each cycle; 5-FU (225 mg/m2/24
hours) during cycles 2 to 4; radiotherapy in 28 fractions with a total dose of 50.4 Gy over 5.5
weeks. Surgery was performed 7 to 10 weeks after completion of all therapies. No grade4
toxicity was detected and the most frequent toxicity was diarrhea. Pathologic complete
response was achieved in 5 out of 32 patients. In another phase II study, bevacizumab was
explored in a combination treatment of capecitabine and radiotherapy [68]. Twenty-five rectal
cancer patients received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over
5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m2
orally twice daily during the radiation). Surgical resection was performed a median of 7.3
weeks later initial treatment. An encouraging pathologic complete response rate was reported
in 8 of 25 patients (32%). Six of 24 patients showed less than 10% viable tumor cells in final
pathological specimens. No patient was reported with grade 3 gastrointestinal toxicity or
significant hematologic toxicity.
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In a recent study, bevacizumab was tested in a combined treatment including the oxaliplatin,
5-FU, and radiotherapy in 26 patients [69]. Patients were initially treated with 1 month of
induction bevacizumab and FOLFOX6, then received 50.4 Gy of radiation and concurrent
bevacizumab (5 mg/kg on Days 1, 15, and 29), oxaliplatin (50 mg/m2/week for 6 weeks), and
continuous infusion 5-FU (200 mg/m(2)/day). This trial was terminated early because of high
incidence of significant grade 3 toxicity. Authors reported 19 (75%) of 25 patients experienced
grade 3 toxicities. Five (20%) out of 25 patients had pathologic response. The effect of bevacu‐
zimab was also studied with erlotinib, a small molecule epidermal growth factor receptor
tyrosine kinase inhibitor in a combination treatment of 5-flurouracil and external beam
radiation in 21 patients [70]. Seven (47%) of 15 patients who completed the therapy and had
surgery achieved pathologic complete response. Reported toxicities were including lympho‐
penia 6 (40%), diarrhea 4 (24%), rash 2 (12%), cardiac ischemia 1(6%), transaminitis (6%) and
mucositis (6%).
Obtained promising pathologic response and observed safety results by the addition of
monoclonal antibodies in neoadjuvant chemoradiation encourages to further explore the role
of these drugs in treatment of locally advanced rectal cancer. On the other hand these targeting
agents are yet to be standard-care-of rectal cancer in neoadjuvant settings.
7. Conclusions
The clinical advances over the last two decades have led to demonstrable improvements in the
outcomes of patients with colorectal cancer and are a testament to the success of multidisci‐
plinary cancer care. Continued development of novel therapeutics in the metastatic setting
will undoubtedly lead to changes in our surgical adjuvant treatments. Refinement in predictive
and prognostic studies will allow us greater ability to tailor the appropriate therapy for
patients, and allow for greater patient’s participation in the shared decision process.
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